Article
Oncology
Atsuro Saijo, Hirokazu Ogino, Nicholas A. Butowski, Meghan R. Tedesco, David Gibson, Payal B. Watchmaker, Kaori Okada, Albert S. Wang, Anny Shai, Andres M. Salazar, Annette M. Molinaro, Jane E. Rabbitt, Maryam Shahin, Arie Perry, Jennifer L. Clarke, Jennie W. Taylor, Mariza Daras, Nancy Ann Oberheim Bush, Shawn L. Hervey-Jumper, Joanna J. Phillips, Susan M. Chang, Norbert Hilf, Andrea Mayer-Mokler, Tibor Keler, Mitchel S. Berger, Hideho Okada
Summary: The combinational immunotherapy with multipeptide IMA950 vaccine and varlilumab induction demonstrated vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor microenvironment.
Review
Immunology
Ye Zheng, Xiaoyu Ma, Shouchang Feng, Hongtao Zhu, Xin Chen, Xingjiang Yu, Kai Shu, Suojun Zhang
Summary: Glioblastoma (GBM), the most malignant subtype of glioma, is resistant to traditional therapies and immunotherapies. Dendritic cell vaccine (DCV) has shown potential as a therapeutic method, but there are challenges to its use.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Yu Zeng, Xin Chen
Summary: The expression of 90K in glioma is correlated with tumor grade, serving as a useful biomarker for malignancy and patient prognosis. Addition of 90K to DC vaccine enhances the immunotherapy effect on GBM.
Review
Oncology
M. Platten, L. Bunse, W. Wick
Summary: The development of anticancer vaccines has been hindered by a lack of suitable tumor-specific antigens, while IDH1R132H mutation generates a shared clonal neoepitope recognized by mutation-specific T-helper cells, providing new directions for certain cancer vaccines.
Article
Immunology
Zheling Chen, Shanshan Zhang, Ning Han, Jiahong Jiang, Yunyun Xu, Dongying Ma, Lantian Lu, Xiaojie Guo, Min Qiu, Qinxue Huang, Huimin Wang, Fan Mo, Shuqing Chen, Liu Yang
Summary: This study enrolled 7 advanced pancreatic cancer patients and successfully applied neoantigen identification and selection, demonstrating that a personalized neoantigen-based peptide vaccine iNeo-Vac-P01 could improve the clinical efficacy limitations of pancreatic cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Clinical Neurology
Lukas Bunse, Theresa Bunse, Christopher Kraemer, Yu-Chan Chih, Michael Platten
Summary: This article reviews recent clinical and translational advances in glioma immunotherapy, with a focus on targets and their cognate immune receptor derivatives as well as concepts to improve intratumoral T cell effector functions.
Article
Oncology
David J. Pinato, Petros Fessas, Alessio Cortellini, Lorenza Rimassa
Summary: Combination immunotherapy is an important treatment approach in hepatocellular carcinoma (HCC) where single-agent immunotherapy has not been successful. The RESCUE trial introduces camrelizumab and apatinib as new options for advanced HCC treatment, sparking debate about the optimal positioning of different combination regimens in liver cancer.
CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Parvin Zamani, Mohammad Mashreghi, Mahere Rezazade Bazaz, Farshad Mirzavi, Mehdi Barati, Fatemeh Zahedipour, Mahmoud Reza Jaafari
Summary: The study showed that a liposomal-based peptide vaccine containing AE36, PADRE, and MPL could induce significant immune responses and potential prophylactic vaccine candidacy in a mouse model of breast cancer.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Oncology
Haiping He, Yulin Cen, Ping Wang, Xu Zeng, Shan Zeng, Xinlong Li, Xiaofei Lu, Chuanhong Zhong, Yang Ming, Ligang Chen, Lilei Peng
Summary: Tumor immunotherapy has the potential to be an effective treatment with minimal damage to the patient's body. However, immune escape phenomenon hinders its effectiveness. The use of molecular mimic vaccines shows promise in reversing tumor-associated immunosuppression.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Engineering, Biomedical
Yanpu He, Celestine Hong, Samantha J. Fletcher, Adam G. Berger, Xin Sun, Mengdi Yang, Shengnan Huang, Angela M. Belcher, Darrell J. Irvine, Jiahe Li, Paula T. Hammond
Summary: By fusing the peptide with STING Delta TM and complexing it with cGAMP, self-assembled cGAMP-peptide-STING Delta TM tetramers are formed, enabling efficient lymphatic trafficking of the peptide. This strategy acts as a protein carrier for the peptide and a potent adjuvant capable of triggering STING signaling, effectively addressing the challenges in peptide vaccine delivery.
ADVANCED HEALTHCARE MATERIALS
(2022)
Article
Oncology
Ryan M. Kahn, Govind Ragupathi, Qin C. Zhou, Alexia Iasonos, Sara Kravetz, Martee L. Hensley, Jason A. Konner, Vicky Makker, William P. Tew, Carol Aghajanian, Paul J. Sabbatini, Roisin E. O'Cearbhaill
Summary: This study investigates the safety, immunogenicity, and clinical outcomes of patients with HGSOC treated with a polyvalent antigen-KLH plus OPT-821 vaccine construct and bevacizumab. The results show that the vaccine is well tolerated with bevacizumab, but treatment response is not associated with improved survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Chemistry, Multidisciplinary
Xuedan He, Shiqi Zhou, Wei-Chiao Huang, Amal Seffouh, Moustafa T. Mabrouk, M. Thomas Morgan, Joaquin Ortega, Scott Abrams, Jonathan F. Lovell
Summary: A new vaccine adjuvant system was developed to induce strong cellular immune responses against multiple tumor cell lines, demonstrating durable immunity. The system showed the importance of stable particle formation for effective immune response induction and could control local and metastatic disease in a therapeutic setting.
Review
Oncology
Montserrat Lara-Velazquez, Jack M. Shireman, Eric J. Lehrer, Kelsey M. Bowman, Henry Ruiz-Garcia, Mitchell J. Paukner, Richard J. Chappell, Mahua Dey
Summary: Immunotherapy combined with standard of care chemo-radiotherapy following surgical resection for newly diagnosed GBM did not show significant improvement in 1-year overall survival or progression-free survival compared to standard care alone. The combination therapy did not lead to a statistically significant increase in severe adverse events grade 3 to 5.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Takumi Kumai, Hidekiyo Yamaki, Michihisa Kono, Ryusuke Hayashi, Risa Wakisaka, Hiroki Komatsuda
Summary: The success of immune checkpoint blockade has demonstrated the potential of immune cells to attack tumors. However, the non-specific activation of immune cells limits the clinical benefit to less than 20% of patients. Peptide-based immunotherapy, by targeting tumor antigens, offers a promising approach to develop tumor-specific immune responses. Recent advancements have shown that peptides, with suitable adjuvants, can elicit robust antitumor responses in both mice and humans.
Article
Oncology
Daniela A. Bota, Thomas H. Taylor, Naomi Lomeli, Xiao-Tang Kong, Beverly D. Fu, Axel H. Schonthal, Samuel Singer, Deborah T. Blumenthal, Frank M. Senecal, Helena Linardou, Evangelos Rokas, Dimitris G. Antoniou, Virgil E. J. C. Schijns, Thomas C. Chen, Joseph Elliot, Apostolos Stathopoulos
Summary: This study reports the efficacy and safety of the therapeutic vaccine SITOIGANAP in patients with recurrent glioblastoma (GBM). The results demonstrate that the addition of SITOIGANAP to existing therapy significantly extended patients' survival compared to historic control values, with minimal toxicity.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Darel Martinez Bedoya, Valerie Dutoit, Denis Migliorini
Summary: CAR T cell therapy has shown significant progress in cancer immunotherapy, with promising results in hematological malignancies and challenges in solid tumors like GBM. Allogeneic CAR T cells may offer advantages over autologous T cells, potentially allowing for multivalent approaches and modification of the tumor microenvironment. Future advancements in genome editing tools could further enhance the effectiveness of allogeneic CAR T cells for the treatment of patients with GBM.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Vassilis Genoud, Denis Migliorini
Summary: Glioblastoma, the most common primary tumor of the central nervous system, has poor therapeutic outcomes, with efforts being made to explore immunotherapy as a potential treatment avenue. Despite success in other cancers, the road to effective immunotherapy for glioblastoma remains long.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Genetics & Heredity
Eliana Marinari, Valerie Dutoit, Sergey Nikolaev, Maria-Isabel Vargas, Karl Schaller, Johannes Alexander Lobrinus, Pierre-Yves Dietrich, Petros Tsantoulis, Denis Migliorini
Summary: Whole-exome sequencing of HGG lesions and distant extraneural lesions confirmed a common glioma origin and identified potential genetic drivers of metastatic dissemination outside the CNS, providing potential therapeutic targets or biomarkers.
NEUROLOGY-GENETICS
(2021)
Meeting Abstract
Oncology
Eugenio Fernandez, Remi Vernet, Emily Charrier, Denis Migliorini, Markus Joerger, Marie-Claude Belkouch, Muriel Urwyler, Olivier Von Rohr, Valentin Saingier, Virginie Ancrenaz, Nicole Grandjean, Emmanuel Lavalliere, Elisabeth Lafferma, Olivier Rubin, Jean Villard, Julien Grogg, Nicolas Mach
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Melita Irving, Evripidis Lanitis, Denis Migliorini, Zoltan Ivics, Sonia Guedan
Summary: CAR-T cell therapy shows great potential for treating B cell malignancies, but translating it to other tumor types remains a challenge. Research is ongoing to develop more sophisticated methods and tools for engineering T cells to overcome limitations of traditional viral vectors.
HUMAN GENE THERAPY
(2021)
Review
Oncology
Luca Paun, Alessandro Moiraghi, Gianpaolo Jannelli, Aria Nouri, Francesco DiMeco, Johan Pallud, Torstein R. Meling, Shahan Momjian, Karl Schaller, Francesco Prada, Denis Migliorini
Summary: Focused Ultrasound (FUS) is a promising therapy in the treatment of high-grade glioma (HGG) due to its non-invasiveness. While the efficacy of FUS-mediated ablation in human HGG patients remains controversial, FUS-mediated Blood-Brain Barrier (BBB) opening shows potential with minimal complications, indicating it may become a reliable technique for improving local chemotherapy delivery and antitumoral immune response in the future. Ongoing trials are expected to provide more data on the impact of FUS-mediated BBB opening on survival outcomes and drug delivery capabilities in HGG patients.
Article
Cell Biology
Mathias Wenes, Alison Jaccard, Tania Wyss, Noelia Maldonado-Perez, Shao Thing Teoh, Anouk Lepez, Fabrice Renaud, Fabien Franco, Patrice Waridel, Celine Yacoub Maroun, Benjamin Tschumi, Nina Dumauthioz, Lianjun Zhang, Alena Donda, Francisco Martin, Denis Migliorini, Sophia Y. Lunt, Ping-Chih Ho, Pedro Romero
Summary: Mitochondrial pyruvate uptake instructs metabolic flexibility for guiding T cell differentiation and antitumor responses.
Review
Oncology
Mikael J. Pittet, Olivier Michielin, Denis Migliorini
Summary: The interaction of tumour-associated macrophages (TAMs) with cancer and stromal cells in the tumour microenvironment enables and sustains most of the hallmarks of cancer. The authors of this Review examine the diversity of TAMs in various cancer indications, which is being revisited with the advent of single-cell technologies, and discuss the functional roles of different TAM states, the prognostic and predictive value of TAM-related signatures as well as approaches involving TAMs that are currently being or will soon be tested in clinical trials.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Editorial Material
Oncology
John T. Schiller, Douglas R. Lowy
Summary: Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, this article revisits the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and provide insights into the clinical development progress and challenges that need to be overcome for wide implementation.
Review
Medicine, General & Internal
Barbara Muoio, Domenico Albano, Francesco Dondi, Francesco Bertagna, Valentina Garibotto, Jolanta Kunikowska, Arnoldo Piccardo, Salvatore Annunziata, Vittoria Espeli, Denis Migliorini, Giorgio Treglia
Summary: The diagnostic accuracy of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in high-grade gliomas (HGG) is high, with a sensitivity of 98.2% and specificity of 91.2%. However, more studies are needed to confirm its promising role in this clinical setting.
Review
Biochemistry & Molecular Biology
Semira Sheikh, Denis Migliorini, Noemie Lang
Summary: CD19 auto-CAR T cell therapy has been successful in treating relapsed and/or refractory non-Hodgkin lymphomas, leading to significant response rates and prolonged remissions. It has gained regulatory approval and is now being considered for earlier lines of therapy.
Review
Cell Biology
Joao Victor Machado Carvalho, Valerie Dutoit, Claudia Corro, Thibaud Koessler
Summary: The treatment of locally advanced rectal cancer requires a combination of neoadjuvant therapy and surgery. Circulating biomarkers have been investigated for their predictive value in predicting response to therapy. However, inconsistent results and limitations in specificity and sensitivity prevent the reliable prediction of tumor response.
Article
Cell Biology
Arthur Bassot, Helena Dragic, Sarah Al Haddad, Laurine Moindrot, Soline Odouard, Francesca Corlazzoli, Eliana Marinari, Alexandra Bomane, Augustin Brassens, Antoine Marteyn, Youssef Hibaoui, Tom J. Petty, Mounira Chalabi-Dchar, Louis Larrouquere, Evgeny M. Zdobnov, Noemie Legrand, Jerome Tamburini, Hubert Lincet, Marie Castets, Mayra Yebra, Denis Migliorini, Valerie Dutoit, Paul R. Walker, Olivier Preynat-Seauve, Pierre-Yves Dietrich, Erika Cosset
Summary: The study identified miR-17-3p, miR-222, and miR-340 as critical miRNAs for GBM patients and showed that their combinatorial modulation efficiently inhibited biological processes, induced cell death, and delayed tumor growth. This suggests that multi-targeting of miR-17-3p, miR-222, and miR-340 could be a promising therapeutic strategy for GBM patients.
CELL DEATH & DISEASE
(2023)
Meeting Abstract
Clinical Neurology
A. Zeitlberger, P. Putora, S. Hofer, P. Schucht, D. Migliorini, A. Hottinger, U. Roelcke, H. Laubli, P. Spina, O. Bozinov, M. Weller, M. Neidert, T. Hundsberger
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Meeting Abstract
Biotechnology & Applied Microbiology
Darel Martinez Bedoya, Eliana Marinari, Francesca Corlazzoli, Shahan Momjian, Valerie Dutoit, Denis Migliorini